Pamorelin (Triptorelin)

Triptorelin, the active ingredient in Pamorelin, is a gonadotropin-releasing hormone (GnRH) agonist presented as a sterile solution for subcutaneous injection use. It is employed in the management of hormone‑dependent conditions such as prostate cancer, endometriosis and assisted reproductive protocols.

GNH USA supplies Pamorelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamorelin is a GnRH‑agonist that modulates the hormonal axis involved in several endocrine‑related conditions.

- Prostate cancer: provides androgen suppression to slow tumor progression. - Endometriosis: induces hypo‑estrogenic state to reduce pelvic pain and lesion growth. - Assisted reproduction: controls ovarian stimulation timing during in‑vitro fertilisation cycles. - Precocious puberty: delays further sexual development by suppressing gonadotropin release. - Uterine fibroids: lessens fibroid size and related bleeding through estrogen reduction.

Triptorelin may elicit a range of adverse reactions, most of which are dose‑dependent and reversible upon discontinuation.

Common Side Effects: - Hot‑spot  :      ---    ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- - Injection site pain - Headache  - Fatigue  - Nausea  - Hot flashes  - Mood   y -   Serious or Rare Side Effects: - Severe allergic   ---  --- --- --- --- - Cardiovascular events  - Bone density loss  - Hormonal crisis  - Severe injection‑site reactions  - Pituitary apoplexy  - Persistent hyper‑prolactinemia  -   g  -  

Triptorepin   g   ewline

t    ewline  \